Pharmacia returns apomorphine

Executive Summary

Nastech is searching for intranasal apomorphine partner following its reacquisition of rights to the Phase II erectile dysfunction drug from Pharmacia as a condition of the Pfizer merger. Pharmacia will reimburse Nastech $13.5 mil. to terminate the deal, and is helping to retain a contract research organization. The companies signed a licensing agreement in February 2002 (1"The Pink Sheet" Feb. 11, 2002, p. 20). Pfizer markets a potential competitor, Viagra (sildenafil). The announcement indicates that the Pfizer/Pharmacia merger is progressing; the deal is expected to close in the first quarter...